HNSBF - Hansa Biopharma AB (publ) (HNSBF) Q2 2024 Earnings Call Transcript

2024-07-18 13:17:06 ET

Hansa Biopharma AB (publ) (HNSBF)

Q2 2024 Results Conference Call

July 18, 2024 08:00 AM ET

Company Participants

Søren Tulstrup - Chief Executive Officer

Matt Shaulis - Chief Commercial Officer and U.S. President

Hitto Kaufmann - Chief Scientific Officer

Evan Ballantyne - Chief Financial Officer

Conference Call Participants

Alexander Kramer - ABG

Matt Phipps - William Blair

Douglas Tsao - H.C. Wainwright

Erik Hultgard - Carnegie

Johan Unnerus - Redeye

Presentation

Operator

Hello everyone, and welcome to the Hansa Biopharma Q2 2024 Conference Call. Today's call is being recorded. For the first part of this call, all participants will be in a listen only mode. Afterwards, there'll be a question-and-answer session. [Operator Instructions].

I will hand the call over to CEO Søren Tulstrup. Please begin.

Søren Tulstrup

Thank you, operator. Good afternoon. Good morning, and welcome to the Hansa Biopharma conference call to review the first half in Q2 results for 2024. I'm Søren Tulstrup, President and CEO of Hansa Biopharma. Joining me today is Evan Ballantyne, Chief Financial Officer; Matt Shaulis, Chief Commercial Officer and US President; and Hitto Kaufmann, Chief R&D Officer.

Please turn to Slide 2. Please allow me to draw your attention to the fact that we'll be making forward-looking statements during this presentation and you should therefore apply appropriate caution. Now, please turn to Slide 3, an overview of today's agenda. They will discuss the progress we made during the first half of 2024 and review our near-term authorities. The presentation should take roughly 15 minutes to 20 minutes after which there will be an opportunity to ask questions during a Q&A session. Please turn to Slide 4 and an overview of our Q2 highlights.

I'm pleased to announce we have delivered our third and second quarter of solid sales with total revenue of SEK54.2 million of this SEK47.1 million can be attributed to Idefirix sales. The strong sales performance we saw in the second quarter is a result of the team successful efforts to expand access to Idefirix for highly sensitized ticket patients across Europe. During the quarter, we secured our first commercial sales in Italy following of reimbursement status in key regions.

To date, we have had commercial sales of Idefirix in all of the top five European markets. We are also seeing strong momentum in our pipeline and clinical development efforts. In May, we announced that ConfIdeS of pivotal Phase 3 U.S. trial and kidney transplantation has been fully randomized. This marks an important milestone for Hansa and following data readout in the second half of 2025, we expect to submit a biologics license application to the U.S. FDA seeking accelerated approval. ...

For further details see: